Nuvation Bio Inc. SEC filings NUVB
Nuvation Bio Inc. has 400 filings in SEC EDGAR's recent list, going back to May 15, 2020. Its latest annual report, Form ARS, was filed on Apr 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
New debt, Other events
|
Jul 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt, Other events
|
Jun 30, 2026 | Jun 24, 2026 |
| 424B5 | Prospectus supplement | Jun 29, 2026 | — |
| 305B2 | Filing | Jun 29, 2026 | — |
| FWP | Free writing prospectus | Jun 26, 2026 | — |
| 424B5 | Prospectus supplement | Jun 25, 2026 | — |
| 8-K |
Current report
Shareholder vote results
|
May 27, 2026 | May 21, 2026 |
| 8-K |
Current report
Results of operations
|
May 4, 2026 | May 4, 2026 |
| 10-Q | Quarterly report | May 4, 2026 | Mar 31, 2026 |
| DEFA14A | Additional proxy material | Apr 21, 2026 | — |
| ARS | Annual report to shareholders | Apr 10, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Apr 10, 2026 | May 21, 2026 |
| S-8 | Employee stock plan registration | Mar 3, 2026 | — |
| 10-K | Annual report | Mar 2, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 2, 2026 | Mar 2, 2026 |
| 25-NSE | Delisting notice | Feb 10, 2026 | — |
| 8-K |
Current report
Material agreement, Results of operations, Regulation FD disclosure
|
Jan 12, 2026 | Jan 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 26, 2025 | Nov 26, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 17, 2025 | Nov 17, 2025 |
| S-8 | Employee stock plan registration | Nov 3, 2025 | — |
| 10-Q | Quarterly report | Nov 3, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2025 | Nov 3, 2025 |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 11, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 23, 2025 | May 21, 2025 |
| 10-Q | Quarterly report | May 7, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 7, 2025 | May 7, 2025 |
| ARS | Annual report to shareholders | Apr 8, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Apr 8, 2025 | May 21, 2025 |
| 8-K |
Current report
Material agreement
|
Mar 25, 2025 | Mar 21, 2025 |
| S-3ASR | Automatic shelf registration | Mar 6, 2025 | — |
| 10-K | Annual report | Mar 6, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 6, 2025 | Mar 6, 2025 |
| 8-K |
Current report
Material agreement
|
Mar 5, 2025 | Mar 3, 2025 |
| 8-K |
Current report
Material agreement, New debt
|
Mar 4, 2025 | Mar 3, 2025 |
| 8-K |
Current report
Officer or director change
|
Feb 12, 2025 | Feb 11, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2024 | Nov 6, 2024 |
| 10-Q | Quarterly report | Nov 6, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 7, 2024 | Oct 7, 2024 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Sep 5, 2024 | Sep 3, 2024 |
| EFFECT | Filing | Aug 15, 2024 | — |
| 424B3 | Prospectus | Aug 15, 2024 | — |
| DEFR14A | Filing | Aug 13, 2024 | — |
| CORRESP | Letter to the SEC | Aug 12, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2024 | — |
| S-3 | Shelf registration | Aug 5, 2024 | — |
| 10-Q | Quarterly report | Aug 5, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2024 | Aug 5, 2024 |
| ARS | Annual report to shareholders | Jul 30, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Jul 30, 2024 | Sep 3, 2024 |
| UPLOAD | Letter from the SEC | Jul 16, 2024 | — |
| CORRESP | Letter to the SEC | Jul 16, 2024 | — |
| PRER14A | Filing | Jul 16, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2024 | — |
| 8-K/A |
Amended current report
Other events
|
Jun 20, 2024 | Apr 9, 2024 |
| CORRESP | Letter to the SEC | Jun 18, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 10, 2024 | — |
| PRER14A | Filing | May 24, 2024 | — |
| PRE 14A | Preliminary proxy statement | May 24, 2024 | Jul 10, 2024 |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| 10-K/A | Amended annual report | Apr 26, 2024 | Dec 31, 2023 |
| S-8 | Employee stock plan registration | Apr 18, 2024 | — |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Officer or director change, Bylaw or fiscal year change
|
Apr 10, 2024 | Apr 9, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Mar 25, 2024 | Mar 24, 2024 |
| S-8 | Employee stock plan registration | Mar 4, 2024 | — |
| 10-K | Annual report | Feb 29, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 29, 2024 | Feb 29, 2024 |
| 8-K |
Current report
Officer or director change
|
Jan 8, 2024 | Jan 8, 2024 |
| 8-K |
Current report
Officer or director change
|
Dec 14, 2023 | Dec 11, 2023 |
| 8-K |
Current report
Officer or director change
|
Nov 27, 2023 | Nov 27, 2023 |
| 8-K |
Current report
Officer or director change
|
Nov 13, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2023 | Nov 2, 2023 |
| 10-Q | Quarterly report | Nov 2, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | Aug 3, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2023 | Aug 3, 2023 |
| 8-K |
Current report
Shareholder vote results
|
May 16, 2023 | May 16, 2023 |
| 10-Q | Quarterly report | May 4, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 4, 2023 | May 4, 2023 |
| ARS | Annual report to shareholders | Apr 11, 2023 | Dec 31, 2022 |
| DEF 14A | Proxy statement | Apr 4, 2023 | May 15, 2023 |
| S-8 | Employee stock plan registration | Mar 16, 2023 | — |
| 10-K | Annual report | Mar 15, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 15, 2023 | Mar 15, 2023 |
| 8-K |
Current report
Other events
|
Mar 2, 2023 | Feb 28, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 23, 2022 | Dec 23, 2022 |
| 10-Q | Quarterly report | Nov 3, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2022 | Nov 3, 2022 |
| S-8 | Employee stock plan registration | Aug 26, 2022 | — |
| 10-Q | Quarterly report | Aug 4, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2022 | Aug 4, 2022 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Other events
|
Aug 1, 2022 | Aug 1, 2022 |
| 8-K |
Current report
Shareholder vote results
|
May 17, 2022 | May 16, 2022 |
| 10-Q | Quarterly report | May 9, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 9, 2022 | May 9, 2022 |
| 424B3 | Prospectus | Apr 11, 2022 | — |
| EFFECT | Filing | Apr 7, 2022 | — |
| DEF 14A | Proxy statement | Apr 4, 2022 | May 16, 2022 |
| POS AM | Filing | Mar 2, 2022 | — |
| 8-K |
Current report
Results of operations
|
Feb 28, 2022 | Feb 28, 2022 |
| 10-K | Annual report | Feb 28, 2022 | Dec 31, 2021 |
| 424B3 | Prospectus | Feb 1, 2022 | — |
| 8-K |
Current report
Results of operations
|
Jan 10, 2022 | Jan 10, 2022 |
| 424B3 | Prospectus | Jan 10, 2022 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 10, 2022 | Jan 10, 2022 |
| 424B3 | Prospectus | Nov 10, 2021 | — |
| 10-Q | Quarterly report | Nov 10, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Agreement ended
|
Oct 28, 2021 | Oct 22, 2021 |
| 424B3 | Prospectus | Aug 12, 2021 | — |
| 10-Q | Quarterly report | Aug 12, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2021 | Aug 12, 2021 |
| S-8 | Employee stock plan registration | Jun 8, 2021 | — |
| 8-K |
Current report
Officer or director change
|
Jun 4, 2021 | Jun 1, 2021 |
| 424B3 | Prospectus | Jun 2, 2021 | — |
| EFFECT | Filing | May 28, 2021 | — |
| POS AM | Filing | May 25, 2021 | — |
| 10-K/A | Amended annual report | May 21, 2021 | Dec 31, 2020 |
| 10-Q | Quarterly report | May 17, 2021 | Mar 31, 2021 |
| 8-K |
Current report
Results of operations
|
May 17, 2021 | May 17, 2021 |
| 8-K |
Current report
Restatement
|
May 14, 2021 | May 14, 2021 |
| EFFECT | Filing | Mar 31, 2021 | — |
| 424B3 | Prospectus | Mar 31, 2021 | — |
| CORRESP | Letter to the SEC | Mar 29, 2021 | — |
| S-1/A | Amended registration statement | Mar 29, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 18, 2021 | — |
| 8-K |
Current report
Officer or director change
|
Mar 11, 2021 | Mar 9, 2021 |
| S-1 | Registration statement | Mar 11, 2021 | — |
| 8-K/A | Amended current report | Mar 11, 2021 | Feb 10, 2021 |
| 10-K | Annual report | Mar 11, 2021 | Dec 31, 2020 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Listing notice, Change to shareholder rights, Auditor change, Officer or director change, Bylaw or fiscal year change
|
Feb 12, 2021 | Feb 10, 2021 |
| 25-NSE | Delisting notice | Feb 11, 2021 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Feb 9, 2021 | Feb 9, 2021 |
| EFFECT | Filing | Jan 20, 2021 | — |
| 424B3 | Prospectus | Jan 20, 2021 | — |
| CORRESP | Letter to the SEC | Jan 19, 2021 | — |
| SEC STAFF LETTER | Filing | Jan 19, 2021 | — |
| S-4/A | Amendment no. 3 to form s-4 | Jan 19, 2021 | — |
| CORRESP | Letter to the SEC | Jan 8, 2021 | — |
| S-4/A | Amendment no. 2 to form s-4 | Jan 8, 2021 | — |
| 425 | Filing | Jan 8, 2021 | — |
| 425 | Filing | Jan 5, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 31, 2020 | — |
| SEC STAFF LETTER | Filing | Dec 30, 2020 | — |
| CORRESP | Letter to the SEC | Dec 18, 2020 | — |
| S-4/A | Amendment no. 1 to form s-4 | Dec 18, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 10, 2020 | — |
| 10-Q | Quarterly report | Nov 16, 2020 | Sep 30, 2020 |
| S-4 | Registration for a merger or exchange | Nov 12, 2020 | — |
| 425 | Form 425 | Oct 23, 2020 | — |
| 425 | Filing | Oct 23, 2020 | — |
| 425 | Filing | Oct 23, 2020 | — |
| 425 | Form 425 | Oct 21, 2020 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 21, 2020 | Oct 20, 2020 |
| 425 | Current report | Oct 21, 2020 | — |
| 8-K |
Current report
Other events
|
Aug 20, 2020 | Aug 20, 2020 |
| 10-Q | Quarterly report | Aug 14, 2020 | Jun 30, 2020 |
| 8-K |
Current report
Other events
|
Jul 10, 2020 | Jul 6, 2020 |
| 8-K |
Current report
Other events
|
Jul 6, 2020 | Jul 6, 2020 |
| 424B4 | Prospectus | Jul 2, 2020 | — |
| EFFECT | Filing | Jun 30, 2020 | — |
| CERT | Nyse certification filing | Jun 29, 2020 | — |
| 8-A12B | Registration of certain classes of securities | Jun 26, 2020 | — |
| S-1/A | Amended registration statement | Jun 23, 2020 | — |
| S-1 | Registration statement | Jun 12, 2020 | — |
| DRS | Filing | May 15, 2020 | — |
Showing 171 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NUVB (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1811063
- Former names
- Panacea Acquisition Corp (until Feb 11, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.